Janux Therapeutics, Inc. (NASDAQ:JANX) Shares Acquired by Lester Murray Antman dba SimplyRich

Lester Murray Antman dba SimplyRich boosted its stake in Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 205.3% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 24,315 shares of the company's stock after acquiring an additional 16,351 shares during the quarter. Lester Murray Antman dba SimplyRich's holdings in Janux Therapeutics were worth $1,301,000 as of its most recent filing with the SEC.

Other institutional investors have also recently added to or reduced their stakes in the company. AQR Capital Management LLC purchased a new position in Janux Therapeutics in the 2nd quarter valued at $215,000. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Janux Therapeutics by 21.9% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,887 shares of the company's stock valued at $87,000 after purchasing an additional 339 shares in the last quarter. Nisa Investment Advisors LLC lifted its holdings in Janux Therapeutics by 639.5% in the 3rd quarter. Nisa Investment Advisors LLC now owns 20,343 shares of the company's stock valued at $924,000 after purchasing an additional 17,592 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its holdings in Janux Therapeutics by 64.7% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 10,033 shares of the company's stock valued at $456,000 after purchasing an additional 3,943 shares in the last quarter. Finally, Chicago Partners Investment Group LLC purchased a new position in Janux Therapeutics in the 3rd quarter valued at $239,000. Institutional investors and hedge funds own 75.39% of the company's stock.

Insider Buying and Selling at Janux Therapeutics

In other Janux Therapeutics news, insider Andrew Hollman Meyer sold 3,334 shares of Janux Therapeutics stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $42.29, for a total value of $140,994.86. Following the completion of the transaction, the insider now directly owns 82,139 shares of the company's stock, valued at $3,473,658.31. The trade was a 3.90 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO David Alan Campbell sold 15,000 shares of the business's stock in a transaction dated Tuesday, December 3rd. The stock was sold at an average price of $67.00, for a total value of $1,005,000.00. Following the transaction, the chief executive officer now directly owns 242,054 shares of the company's stock, valued at approximately $16,217,618. This represents a 5.84 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 86,668 shares of company stock valued at $4,872,515 in the last three months. 29.40% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

JANX has been the topic of a number of research reports. Stifel Nicolaus raised their price objective on Janux Therapeutics from $70.00 to $115.00 and gave the company a "buy" rating in a report on Tuesday, December 3rd. BTIG Research lifted their price target on Janux Therapeutics from $82.00 to $100.00 and gave the stock a "buy" rating in a report on Tuesday, December 3rd. Cantor Fitzgerald reiterated an "overweight" rating and set a $200.00 price target on shares of Janux Therapeutics in a report on Wednesday, December 11th. Leerink Partnrs upgraded Janux Therapeutics to a "strong-buy" rating in a report on Friday, November 22nd. Finally, William Blair reiterated an "outperform" rating on shares of Janux Therapeutics in a report on Friday, January 10th. One research analyst has rated the stock with a hold rating, ten have given a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, Janux Therapeutics has a consensus rating of "Buy" and a consensus target price of $89.90.

Janux Therapeutics Stock Down 2.2 %

NASDAQ JANX traded down $0.80 during trading on Friday, hitting $36.37. The stock had a trading volume of 1,132,331 shares, compared to its average volume of 1,007,999. The company has a market capitalization of $1.91 billion, a PE ratio of -31.09 and a beta of 3.16. The firm has a 50 day moving average price of $48.79 and a 200 day moving average price of $48.03. Janux Therapeutics, Inc. has a twelve month low of $8.28 and a twelve month high of $71.71.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.